Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
PHAT Stock Chart & Stats
$12.56
-$0.22(-3.06%)
At close: 4:00 PM EST
$12.56
-$0.22(-3.06%)
Day’s Range― - ―
52-Week Range$2.21 - $18.31
Previous CloseN/A
Volume285.74K
Average Volume (3M)943.04K
Market Cap
$989.71M
Enterprise Value$852.59M
Total Cash (Recent Filing)$129.97M
Total Debt (Recent Filing)$2.71M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
May 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding78,798,710
10 Day Avg. Volume1,120,753
30 Day Avg. Volume943,045
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.76
Price to Sales (P/S)6.91
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue4.87
Enterprise Value/Gross Profit5.59
Enterprise Value/Ebitda4.95
Forecast
1Y Price Target
$24.13Price Target Upside92.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$314.17M
Bulls Say, Bears Say
Bulls Say
Balance Sheet & FinancingEquity offering and a restructured term loan that reduced principal and lowered interest enhance financial flexibility and support the company's plan to reach operating profitability.
Commercial TractionSurging VOQUEZNA prescriptions for gastroesophageal reflux disease and non-erosive reflux disease point to accelerating commercial traction and potential market share gains among patients not adequately served by proton pump inhibitors.
Guidance & Cost DisciplineRevenue guidance above consensus combined with operating expenses coming in below expectations prompted analysts to raise near-term revenue forecasts, bolstering upside to profitability.
Bears Say
Forecast RiskAnalyst's slight reduction to a later-period revenue projection signals caution on sustaining sales momentum and introduces downside risk to forward estimates.
Sales Channel RiskUncertainty about whether expansion will require substantial engagement with primary care physicians raises execution risk and could increase sales costs and slow market penetration.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $2.21 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market cap is $989.71M.
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Feb 26, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.122.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -0.27.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 78,798,710 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went up 10.065%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.13 (92.12% Upside)
$24.13 (92.12% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 216.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.35%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and financial progress: very strong revenue growth (217% YoY), disciplined expense reductions, improved cash profile via a $130M equity raise and favorable term loan modifications, near-full sales force, and clear guidance to reach operating profitability in Q3 2026 and cash flow positivity in 2027. Key challenges cited include persistently high gross-to-net discounts (55%–59%), remaining absolute expense levels, seasonality and short-term prescription volatility, limited broad Medicare coverage, covenant timing considerations, and competitive risk. On balance, the positive execution items (revenue growth, cost control, capital structure improvements, and commercial traction) outweigh the challenges described.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$24.13
▲(92.12% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
10.92% Insiders
10.20% Mutual Funds
38.67% Other Institutional Investors
32.11% Public Companies and Individual Investors